Current treatments of HF rely almost entirely on altering the neurohormonal milieu, using agents such as angiotensin converting enzyme (ACE) inhibitors, angiotensin receptor blockers, and beta-adrenergic blockers to improve cardiac function and reduce mortality. The gene discussed is ACE; the disease is hydrops fetalis.